Amphinex
- This topic has 0 replies, 1 voice, and was last updated 10 years, 5 months ago by
.
-
Posts
-
FIRST PATIENT TREATED IN THE STUDY OF AMPHINEX IN PATIENTS WITH BILE DUCT CANCER .
” reported today that the first patient has been treated in the phase I/II study of Amphinex in combination with the cytotoxic agent gemcitabine in patients with bile duct cancer (cholangiocarcinoma). The first patient was treated at the University Hospital Aintree, Liverpool, UK.
Coordinating Investigator, Dr. Richard Sturgess at Aintree, said: “Bile duct cancer is a devastating disease with a very clear need of better treatment methods. Bile duct cancer has a remarkable resistance to chemotherapy and these patients are lacking good alternative treatment options. PCI of gemcitabine with Amphinex represents a new and innovative treatment concept that could potentially produce significant local tumour response in these patients. The study is well designed to demonstrate the potential clinical benefit of Amphinex induced PCI of gemcitabine in bile duct cancer patients and I look forward to working with my fellow investigators on this study.”
- The forum ‘New Developments’ is closed to new topics and replies.